Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPC 1

Next Previous
Drug Profile

OPC 1

Alternative Names: AST-OPC1; GRNOPC 1; hESC-derived oligodendrocyte progenitor cells (OPC) - Geron/University of California; Oligodendrocyte progenitor cells - Lineage Cell Therapeutics; OPC-1

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics; Lineage Cell Therapeutics
  • Class Neural stem cell therapies; Pluripotent stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Spinal cord injuries
  • No development reported Ischaemic stroke; Multiple sclerosis
  • Discontinued Alzheimer's disease; Canavan disease

Most Recent Events

  • 13 Jun 2025 9444124 - no updates
  • 25 Mar 2025 Lineage Cell Therapeutics plans the phase I DOSED trial for Spinal cord injuries in second quarter of 2025 (NCT06841770)
  • 31 Jan 2025 US FDA approves Lineage Cell Therapeutics' IND amendment to phase I DOSED trial in Spinal cord injury

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top